Please ensure Javascript is enabled for purposes of website accessibility

Aurora Cannabis and Tilray to Supply Experimental French Medical Cannabis Program

By Rich Duprey - Jan 27, 2021 at 11:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They were chosen as two main suppliers among four marijuana producers.

Aurora Cannabis (ACB -38.46%) and Tilray (TLRY) were among a handful of international marijuana producers chosen to participate in a new French medical marijuana experiment.

The National Agency for Medicines and Health Products Safety (ANSM) is trialing a small-scale, 18- to 24-month program to supply patients with medical marijuana free of charge. Partnering with a France-based pharmaceutical establishment, producers will supply up to 3,000 patients with free product while complying with pharmaceutical standards, including Good Manufacturing Practices (GMP).

The experimental program was announced in October 2020 and is expected to begin by March 31, the costs for which will be borne by the suppliers. Suppliers will not be compensated for their participation either.

Lab technician placing marijuana in test tube

Image source: Getty Images.

Playing catchup in marijuana

Tilray said its products are being supplied to French patients for whom existing treatments do not provide sufficient relief from their symptoms, as well as for therapeutic indications, such as neuropathic pain, epilepsy, certain persistent symptoms in cancer and anti-cancer, multiple sclerosis, and other indications.

Both Tilray and Aurora have been chosen as main suppliers for the program, but Tilray will also serve as a backup supplier in the event of a shortfall. Two other cannabis producers, Israel's Panaxia, and the U.K.'s Emmac Life Sciences, were also chosen as suppliers, though Emmac will only serve as a substitute for shortfalls. Panaxia will be both a main supplier and backup.

The program was begun after France was accused of falling "alarmingly behind" in the administration of medical cannabis even though legislators had approved the experiment in 2019.

Because France has yet to develop a domestic source of medical marijuana, the program is relying upon foreign sources of cannabis for the experiment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
$1.68 (-38.46%) $-1.05
Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.